Immunomodulatory effects and improved outcomes with cisplatin- versus carboplatin-based chemotherapy plus atezolizumab in urothelial cancer
Galsky et al. demonstrate that durable cancer control with cisplatin versus carboplatin is most prominent in patients with pretreatment tumors demonstrating features of restrained adaptive immunity. In vitro, they demonstrate that cisplatin versus carboplatin exerts direct immunomodulatory effects on cancer cells, promoting dendritic cell activation and antigen-specific T cell killing.